Published by Business Insights
Table of contents | Brochure | Order form
Pages: 209, Coverage: Global, Published: April 2009
Single user copy: $3,835

“The global autoimmune market generated sales of $31.9bn in 2007, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013….”

Autoimmune disorders have been one of the most prominent growth segments in the pharma industry over the last decade. A growing patient population and high levels of unmet need are the main drivers of market
growth, and novel biologics are increasingly helping to fulfill patient need. Study findings have also shown that the early use of anti-TNF drugs can help to halt/reverse disease progression, and this has expanded patient populations even further.

‘The Autoimmune Market Outlook to 2013′ is a new report published by Business Insights that provides comprehensive coverage of major markets within the global autoimmune area, incorporating a detailed epidemiological analysis of key indications and the main factors impacting their prevalence. Current leading brands of treatment within each indication are analysed and eight of the market’s leading players are profiled. With coverage of over 95% of the total market for autoimmune products, this report reviews the factors and underlying trends that are shaping the market and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2009-13 period are also provided.

Assess leading brands of treatment, identify growth opportunities and compare the outlooks of leading companies in the autoimmune market…

Use this report to:

• Assess patient potential, treatment trends and sales patterns of major autoimmune indications over the period 2009-13, with this report’s coverage of osteoarthritis, rheumatoid arthritis, crohn’s disease, systemic lupus erythematosus, ulcerative colitis and multiple sclerosis markets across Japan, France, Germany, Italy, Spain, the UK and the US.
• Compare the market performance and strategic positioning of major pharma companies’ autoimmune portfolios with this
  report’s evaluation of the franchises and market shares of Amgen, Abbott, J&J, Pfizer, Novartis, Wyeth, Roche and Astellas.
• Evaluate the autoimmune pipeline compounds of leading companies with this report’s detailed analysis of clinically
  differentiated pipeline products by indication, and sales forecasts for key R&D pipeline products to 2013.
• Discover the market dynamics of the autoimmune area and understand the impact of recent events by assessing key
  market trends, growth drivers and the latest issues affecting product development.

Our Guarantee of Quality and Value
We stand 100% behind the quality and value of our products. If you are dissatisfied, simply let us know and we will send you an immediate refund for your entire order - no questions asked.

Click here for a printable order form that you can fax or mail at a later time.